Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ACOR

Acorda Therapeutics (ACOR) Stock Price, News & Analysis

Acorda Therapeutics logo

About Acorda Therapeutics Stock (NASDAQ:ACOR)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.66
$15.60
52-Week Range
N/A
Volume
416,900 shs
Average Volume
119,299 shs
Market Capitalization
$820 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ACOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acorda Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACOR Stock News Headlines

INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Acorda: I did not accept money from Guo
See More Headlines

ACOR Stock Analysis - Frequently Asked Questions

Acorda Therapeutics, Inc. (NASDAQ:ACOR) released its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported ($28.60) earnings per share for the quarter, beating the consensus estimate of ($31.20) by $2.60. The biopharmaceutical company had revenue of $31.46 million for the quarter, compared to the consensus estimate of $30.57 million. Acorda Therapeutics had a negative trailing twelve-month return on equity of 2,206.93% and a negative net margin of 214.95%.

Acorda Therapeutics's stock reverse split on Monday, June 5th 2023.The 1-20 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Acorda Therapeutics investors own include Meta Platforms (META), Sangamo Therapeutics (SGMO), GE Aerospace (GE), NVIDIA (NVDA), Exxon Mobil (XOM), Energy Transfer (ET) and CymaBay Therapeutics (CBAY).

Company Calendar

Last Earnings
11/09/2021
Today
7/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ACOR
CIK
1008848
Employees
111
Year Founded
1995

Profitability

EPS (Trailing Twelve Months)
($203.83)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$252.85 million
Net Margins
-214.95%
Pretax Margin
-251.65%
Return on Equity
-2,206.93%
Return on Assets
-83.28%

Debt

Debt-to-Equity Ratio
3.07
Current Ratio
0.33
Quick Ratio
0.26

Sales & Book Value

Annual Sales
$117.63 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
0.02
Book Value
($127.17) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
1,240,000
Free Float
1,210,000
Market Cap
$820 thousand
Optionable
No Data
Beta
1.40

Social Links

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:ACOR) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners